This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into Gilead's twice-yearly Lenacapavir 100 percent efficacy compared to daily Truvada for HIV

Ticker(s): GILD

Who's the expert?

Institution: Infectious Disease Consultants Medical Group

  • Infectious Disease Specialist at Infectious Disease Consultants Medical Group
  • Manages about 150 patients with HIV 
  • Familiar with and have prescribed all of the following HIV treatments by Gilead Sciences; Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada, Tybost, and Viread.

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.